![James Lillie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
James Lillie served as the Chief Scientific Officer at OvaScience, Inc. in 2018.
Prior to that, he earned a doctorate degree from Harvard University and an undergraduate degree from Wesleyan University.
Eerdere bekende functies van James Lillie
Bedrijven | Functie | Einde |
---|---|---|
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Hoofd Techniek/Wetenschap/O&O | 07-12-2018 |
Opleiding van James Lillie
Harvard University | Doctorate Degree |
Wesleyan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |